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ABSTRACT:
Sialic acids (Sias) are a group of a-keto acids with a
nine-carbon backbone, which display many types of mod-
ifications in nature. The diversity of natural Sia presenta-
tions is magnified by a variety of glycosidic linkages to
underlying glycans, the sequences and classes of such gly-
cans, as well as the spatial organization of Sias with their
surroundings. This diversity is closely linked to the
numerous and varied biological functions of Sias. Rela-
tively large libraries of natural and unnatural Sias have
recently been chemically=chemoenzymatically synthesized
and=or isolated from natural sources. The resulting sialo-
glycan microarrays have proved to be valuable tools for
the exploration of diversity and biology of Sias. Here we
provide an overview of Sia diversity in nature, the
approaches used to generate sialoglycan microarrays, and
the achievements and challenges arising.VC 2013 Wiley
Periodicals, Inc. Biopolymers 99: 650–665, 2013.
Keywords: sialic acids; diversity; sialoglycan microarrays
This article was originally published online as an accepted pre-
print. The “Published Online” date corresponds to the preprint
version. You can request a copy of the preprint by emailing the
Biopolymers editorial office at biopolymers@wiley.com
INTRODUCTION
D
NA, RNA, proteins, and glycans are the four biopol-
ymers essential to all known life forms.1,2 Glycans
differ from the other types of biopolymers in several
ways. Glycan biosynthesis is not template-driven
and cannot be accurately predicted by any known
method. In addition, glycans form branched structures, dis-
play numerous modifications, and have far more diversity in
overall structure. These and other differences partly account
for the historical lag in chemical and biological studies of
glycans, compared to the other classes of biopolymers. The
development of technologies to elucidate the structures and
functions of these complex molecules have recently drawn
increasing scientific interest and it is now well appreciated
that glycans play vital roles in numerous complex biological
processes and systems,3,4 a fact recently recognized by a spe-
cial report from the US National Academies, urging greater
investments in this area.5
Among the various monosaccharide building blocks of
glycans, sialic acids (Sias) are rather unusual. They are typi-
cally found as terminal residues on the glycan chains of ver-
tebrate glycoconjugates. In contrast to most other common
monosaccharides, which are aldoses or ketoses with five or
six carbons, Sias are a-keto acids with a nine-carbon back-
bone (Figure 1). Furthermore, the types of natural modifica-
tions found on Sias far exceed that of any other
monosaccharides (Figure 1).6–13 Additional differences
include the limited occurrence of Sias (primarily in the deu-
terostome lineage of animals and certain types of bacteria),
as well as its unusual form of nucleoside monophosphate-
activated sugar donor (CMP-Sia).12 These and other distinct
features of Sias contribute to higher structural complexity
and the potential for more unique and varied biological
functions, in comparison to other monosaccharides.
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Accumulating evidence also indicates that evolutionary
selection forces play a critical role in the diversification of gly-
cans, which are intrinsically linked to their biological func-
tions.14–16 Among various glycan classes, Sias appear to be the
most rapidly evolving. In keeping with the recommended style
for this contributed article, we will not attempt to cover the
whole field; rather we will review our own work within the
context of the field, including our personal insights, and specu-
late on where research is headed in the future. We will begin by
briefly discussing the diversity and biology of Sias in nature,
with examples from our own labs in the context of work of
others. Recent advances in the synthesis of sialosides and the
application of sialoglycan microarrays will then be reviewed,
from our perspective.
DIVERSITYAND BIOLOGYOF SIALIC ACIDS
IN NATURE
Natural Diversity and Biology of Sialic Acid forms
and Modifications
The two core Sia forms are neuraminic acid (Neu) and 2-keto-
3-deoxy-D-glycero-D-galacto-nononic-acid (Kdn) (Figures 2a
and 2b). More than 50 different types of naturally occurring
Sia variants (c.f., Table 1 in Ref. 12) have been found based on
modifications to these two forms, including 5-N-acetylation,
hydroxylation of 5-N-acetyl group, O-acetylation, O-methyla-
tion, O-lactylation, O-sulfation, O-phosphorylation, and intra-
molecular lactam or lactone formation.6–13 Among the diverse
naturally occurring Sias, N-acetylneuraminic acid (Neu5Ac)
and N-glycolylneuraminic acid (Neu5Gc) are the two most
abundant ones in mammals (Figures 2c and d). The nine-
carbon Sia backbone is also shared by other nonulosonic
acids (NulOs) that are found in prokaryotes, such as legiona-
minic acid (Leg) and pseudaminic acid (Pse) (Figures 2e and
2f).17–20 This review will focus on the more common Sias,
some of which are shared by animals and pathogenic bacteria.
The diversity of Sia forms and modifications are closely
associated with biological functions in both intracellular and
intercellular environments, from early discovered effects on
the physical properties of glycoproteins,21 to their protective
and masking roles,22 and to more recently established media-
tion and modulation of numerous biological processes
including signaling, fertilization, immunity, growth and differ-
entiation.6–12,23 Among the many Sia O-modifications, 9-O-
acetylation is best studied. When modified by O-acetyl
group(s), Sias can be blocked from recognition by intrinsicFIGURE 1 Sialic acid diversity. The nine-carbon Sia backbone is
shown in a configuration. Most known Sia modifications, at posi-
tions C-1, C-2, C-4, C-5, C-7, C-8, and C-9, around the backbone
are indicated. Figure modified with permission, from Ref. 13.
FIGURE 2 Examples of naturally occurring sialic acid and nonu-
losonic acid structures. Neu (a) and Kdn (b) are the two most basic
Sia forms. Neu5Ac (c) and Neu5Gc (d) are derived from Neu and
are the two most abundant Sia structures found in mammals. Leg
(e) and Pse (f) are two representatives of the nonulosonic acid fam-
ily that used to be known as the “bacterial Sias.”
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lectins such as Siglecs (Sia-binding immunoglobulin-like lec-
tins).24,25 O-Acetylation can also modulate interactions
between Sias and microbial proteins, in a manner either bene-
fiting or harming the host.23,26–30 O-Methylation has been
found to make Sias resistant to sialidases, indicating a mecha-
nism of biological significance.31
One variation at the C-5 position has generated some
uniquely interesting questions related to human evolution and
disease.32 Specifically, hydroxylation of Neu5Ac at the 5-N-ace-
tyl group forms Neu5Gc, a molecule that differs from Neu5Ac
by a single oxygen atom (Figures 2c and 2d). Humans lost the
ability to synthesize Neu5Gc due to a 92 bp exon deletion in
the CMAH gene encoding CMP-Neu5Ac hydroxylase,33,34
which occurred 3 million years ago.35 However, Neu5Gc can
be metabolically incorporated into human cells and tissues, via
human consumption of Neu5Gc-rich foods such as red
meat,36,37 even in the face of circulating anti-Neu5Gc antibod-
ies (Abs) in human blood.38,39 The interactions between these
“xeno-autoantigens” and “xeno-autoantibodies” are currently
postulated to have numerous effects on human diseases,
ranging from induction of chronic inflammation, tumor pro-
gression=suppression, effects on biotherapeutic molecules and
cells,40–46 and even to xenotransplantation rejections.47–52
Moreover, certain bacterial toxins preferentially recognize
glycan epitopes containing metabolically incorporated
Neu5Gc.53
Natural Diversity and Biology of Sia Linkages and
Underlying Glycans
Sias are glycosidically linked via C-2 to underlying glycans
(Figure 1). They can be attached to an underlying galactose
(Gal) residue via a2-3, a2-4, or a2-6 linkage, to N-acetylgalac-
tosamine (GalNAc) via a2-6 linkage, to N-acetylglucosamine
(GlcNAc) via a2-4 or a2-6 linkage, or to another Sia via a2-8
or a2-9 linkages.13 The structural diversity of the underlying
glycan structures and modifications further increase the com-
plexity of Sia-containing molecules. Combinations of the mul-
tiple forms of Sias, different sialyl linkages, and diverse
underlying glycans generate many thousands of possible Sia
presentations.
This diversity of Sia linkages and underlying glycans is
known to be biologically relevant. One well-known example is
the recognition of different Sia linkages by human and avian
adapted influenza A viruses.54 Although the human adapted
ones bind Siaa2-6Gal preferentially, the avian adapted ones
prefer Siaa2-3Gal.27,55–57 The relative expression level and dis-
tribution of Siaa2-6Gal and Siaa2-3Gal in host respiratory
tract are believed to play an important role in the infection and
transmission of these viruses.58,59 Endogenous lectins such as
Siglecs also have distinct Sia ligand preferences. Human Siglec
2 (CD22), for example, selectively recognizes a2-6-linked
Sias,60 but human Siglec-1 (sialoadhesin) prefers a2-3-linked
Sias.61 In addition, Sia linkage to the underlying glycans plays
a role in the progression and spread of human malignancies.
For example, carcinoma behavior can be modulated by a2-6-
sialylation on N-glycans.62–66 Moreover, underlying glycans
can also influence or even determine Sia binding events. Sias
with an underlying Lewis x or Lewis a structure are preferen-
tially recognized by selectins, and sulfation at the C-6 position
of an underlying Gal or GalNAc residue further enhances the
binding affinity.67–70 Additionally, different underlying glycans
capped with the same a2-6 linked Sia were found to show
markedly different binding affinities to CD22.71 Numerous
other such examples could be cited.
Natural Diversity and Biology of Polysialic Acids
Sia-containing homopolysaccharides and heteropolysacchar-
ides have been found in both animals and bacteria.7,17,72–76
Homo-PolySias are found in a few animal glycoproteins, such
as a2-8-linked PolySia on the N-glycans of the neural cell adhe-
sion molecule (NCAM) and on O-glycans of some fish egg gly-
coproteins. The capsular polysaccharides of certain pathogenic
bacteria can express a2-8-, a2-9, or alternating a2-8- and a2-9-
linked Sias polymers. Heteropolysaccharides containing
[-4Siaa2-6Gala1-] and [-4Siaa2-6Glca1-] repeats have also
been found on the capsular polysaccharides of N. meningitidis
serotypes W135 and Y, respectively.77 PolySia chains based on
Neu5Ac, Neu5Gc, Kdn, or Leg building blocks have been
reported, and the inter-residue linkages can vary from a2-8,
a2-9, to a2-4, and to a2-5-OglycolylNeu5Gc.
75 The degree of
polymerization and O-acetylation,78,79 homo- or hetero-
polymerization, and the dynamic equilibrium between polylac-
tones and polycarboxylates further add to the complexity.80,81
Altogether, there is a considerable range of diversity in polySia
chains.
Natural Diversity and Biology of Sialoglycans in
Clustered Saccharide Patches
The concept of “clustered saccharide patches” was first sug-
gested in the context of understanding selectin ligands,67 and
was recently updated to take new evidence into account.82 Cell
surface glycans can be imagined as the outermost aspects of a
tropical rainforest canopy, or more accurately, in a more
dynamic fashion as a kelp bed or coral reef in the ocean (anal-
ogy suggested by P. Gagneux). Viewed in this manner, one can
appreciate the importance of considering the glycome as a
whole when studying glycan-based interactions. Such clustered
saccharide patches are proposed to involve multiple glycan
652 Deng, Chen, and Varki
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components and their surroundings. Thus multiple copies of
the same glycan or multiple copies of different glycans, or gly-
cans and nonglycan structures including adjacent sulfates or
peptide sequences on the same scaffold=carrier or on different
ones, can participate to make up clustered saccharide patches.
Indeed, clustered saccharide patches comprised of Sia and
adjacent sulfates or peptide sequences were reported as ligands
for selectins.70,83–85
A similar analogy can be applied to the sialome, as a subset
of the glycome (Figure 3).86 Five hierarchical levels of Sia struc-
tural and spatial complexities can be conceived of, in analogy
to the leaves=flowers, stems, branches, trees and the forest,
respectively. This theoretical concept is supported by accumu-
lating experimental evidence.82 For example studies of Ab
binding to Sia-containing ligands revealed that in certain cases,
a complex of several sialylated glycans would generate specific
binding, despite the fact that a single glycan from the complex
was not adequate for recognition.87,88 Another example
involves the “glycosynapse,” where Sia epitopes of the glycans
in the cellular surface microdomains play an important func-
tional role. The Sia epitopes cluster with other components in
the microdomains and together they mediate cell adhesion and
signaling to influence the cellular phenotypes.89 Sia-containing
clustered saccharide patches on RBCs of different blood types
can also explain the differential binding of Sia-recognizing pro-
teins in relation to ABO blood group polymorphisms in
humans.90 Furthermore, evidence for Siglec or Ab recognition
of bacterial capsular polysaccharides exists, indicating the pres-
ence of Sia-containing clustered saccharide patches on
pathogens.91,92
SIALIC ACID RECOGNIZING PROTEINS
Many functional roles of glycans are realized or modulated by
interactions with glycan-binding proteins (GBPs).93–95 Gly-
can–glycan interactions also play a critical role in biological
processes such as cell–cell recognition and membrane organi-
zation, but that aspect will not be discussed here. Interested
readers are referred to relevant reviews.96,97
The variety and importance of Sias as ligands in glycan–
protein recognition phenomena were extensively reviewed as
well.98–102 A large number of Sia-binding proteins have already
been identified in viruses, bacteria, plants, invertebrates and
vertebrates, and this number continues to grow. Besides
exploring their occurrence and identifying their cognate
ligands, special emphasis has been placed on studying Sia-
binding proteins from an evolutionary point of view, together
with their biological significance in human health and disease,
especially in immunity, infectious disease and cancer biol-
ogy.14,23,103,104 In addition to Sia-binding lectins, Abs that rec-
ognize Sias have attracted considerable research interest, and
the discovery of cancer biomarkers involving Sia and Sia-
recognizing Abs has become an active research area.46,105,106
For example, co-existence of Neu5Gc and anti-Neu5Gc
Abs in human body represents a unique human phenom-
enon.38–41,43,44,46 Another class of Sia-recognizing proteins are
Sia-recognizing enzymes including sialyltransferases and siali-
dases. These enzymes are essential to the chemistry and biology
of Sias.102 The extensive literature on this subject is not
reviewed here. However, examples of their use in sialochemis-
try will be presented in the following section.
SYNTHESIS OF SIALOGLYCANS BEARING
NATURAL AND UNNATURAL SIAS
In nature, the majority of modifications on Sias are added after
the sialoglycosidic bond formation (so called carbohydrate
postglycosylational modifications or PGMs).107 One clear
exception is the formation of Neu5Gc from Neu5Ac, which
takes place at the CMP-Sia level.108–110 Another exception is
the formation of O-acetylated Neu5Ac-containing capsular
polysaccharides, possibly by direct transfer of O-acetylated
Neu5Ac from O-acetylated CMP-Neu5Ac.111 It is also likely
that one form of mammalian O-acetylation takes place at the
CMP-Sia level.112 The gene sequences for most of the enzymes
responsible for adding modifications to the Sia residues in sia-
loglycans have not been identified to date. The few exceptions
include an O-acetyltransferase from Campylobacter jejuni,113
an O-acetyltransferase for the capsular polysaccharide of Neis-
seria meningitidis serogroups C, W-135, and Y,79,114 and a can-
didate for a vertebrate enzyme.115 Therefore, it is impractical
to synthesize the majority of sialosides containing naturally
occurring postglycosylational modifications in vitro, by totally
following natural biosynthetic pathways. Among various
chemical and chemoenzymatic methods developed for the syn-
thesis of sialoglycans bearing natural and unnatural Sias, the
one-pot multienzyme (OPME) chemoenzymatic sialylation
method116 is the most efficient for generating libraries of sialo-
sides102 that can be used for sialoglycan microarray studies. In
this approach, naturally occurring and non-natural Sia forms,
or their six-carbon precursors such as derivatives of N-acetyl-
mannosamine (ManNAc) or mannose, can be synthesized
chemically or enzymatically. These can then be used as sub-
strates, by a CMP-Sia synthetase and a suitable sialyltransferase
in the absence or the presence of a Sia aldolase, for the synthe-
sis of desired sialoglycans. Diverse sialosides can be synthesized
due to unusual promiscuities of sialyltransferases and other
related sialoside biosynthetic enzymes, including Sia aldolases
and CMP-Sia synthetases, toward substrate modifications.
Obtaining a broad array of sialyltransferases,117–120 CMP-Sia
Sia Diversity and Sialoglycan Microarrays 653
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synthetases,121,122 and Sia aldolases,122,123 with high expression
levels, good solubility and high activities from bacterial species
has made the preparative-scale and even large-scale prepara-
tion of comprehensive libraries of sialoglycans a reality.
Designing enzyme mutants based on protein crystal structures
also enables the expansion of the available sialoglycan products
and renders the synthetic and purification schemes more effi-
cient.124–126
FIGURE 3 Analogy of the sialome to the canopy of a forest. Five hierarchical levels of structural
and organizational complexities are compared. Sia structures are assimilated with tree leaves and
flowers (a); Sia linkages are compared to tree stems (b); Underlying glycans are like branches of
trees (c); Glycan classes are compared with the tree trunks (d); and finally the spatial organization
of glycans and their surroundings are assimilated to the entire forest (e). Figure reproduced with
permission.86
654 Deng, Chen, and Varki
Biopolymers
STUDIES OF SIA DIVERSITYAND BIOLOGY
USING SIALOGLYCAN MICROARRAYS
As discussed above, interactions between glycans and GBPs
underlie much of the biological significance of glycans. The
advent of glycan microarrays has revolutionized the screening
of GBP specificities and fueled the discovery of new GBPs, pro-
viding invaluable information in a high-throughput manner.
During the years after its introduction in 2002,127,128 glycan
microarray studies have extended by development of glycan
libraries and immobilization chemistries, proof-of-principle
demonstrations, discovery of novel GBPs and their binding
specificities, as well as applications in vaccine=inhibitor identi-
fication and biomarker discoveries.127–137 Here, we focus on
discussing the development of a subclass of such arrays, the
sialoglycan microarrays, and their versatile utility in studying
Sia diversity and biology.
Natural and Synthetic Sialoglycan Libraries
To date, one of the most widely used glycan libraries is the one
developed by the Consortium for Functional Glycomics
(CFG). It consists of over 760 glycan structures (610 mamma-
lian glycans and 153 microbial glycans) of various types,
including a total of around 170 Sia-containing structures
(Table I) (http:==www.functionalglycomics.org). However,
quite a few Sia-containing structures in this sialoglycan library
have an overlapping or identical terminal di-=tri-
=tetrasaccharide, some varying merely in spacer structures.
Nevertheless, sialoglycan microarrays comprised of 50–90 of
these structures have been readily produced and applied in var-
ious studies.138–143 During the past few years, Paulson’s group
has been developing chemical and chemoenzymatic methods
to create a large library of sialoside analogues (Table I).144–146
In 2008, Blixt et al.144 utilized 9-azido-Neu5Ac intermediates
and synthesized a library of 44 sialoside analogues bearing un-
natural acyl substituents at the C-9 position, among which 16
were a2-3-linked and 28 a2-6-linked. In 2012, Rillahan et al.
took advantage of click chemistry and further developed the
idea of using a minimum quantity of synthetic sialoglycan ana-
logues on microarrays to screen for high affinity Siglec-binding
ligands.145 This time, a considerably larger library was gener-
ated thanks to the facile copper catalyzed azide-alkyne cycload-
dition (CuAAC) chemistry. Besides modifications at the C-9
position, C-5 modified Sias were also produced. In total, 224
Sia-analogues with either a2-3 or a2-6 linkages, and with lac-
tose as underlying glycan, were produced. It is noteworthy that
these compounds were printed on glycan microarrays for
screening without column purifications, resulting in higher
throughput than the previous effort.144 However, most of the
Sias on these arrays are unnatural ones. Another sialoglycan Ta
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library comes from the Feizi group, which consists of more
than 700 naturally derived and then chemically tagged neogly-
colipids.147 Among these, there are about 120 sialoglycans with
different Sia forms and linkages, and underlying glycans
(Table I).148–151 This library of sialoglycans differs from most
others by the nature of glycan source, that is, they are derived
from natural sources instead of chemically built as in most
other cases. It also contains a few a2-9 linked Sias that other
major sialoglycan libraries lack.150 Our own labs have been
studying the diversity and biology of naturally occurring Sias
and are especially interested in the chemistry and biology of
the nonhuman Sia molecule, Neu5Gc, as well as various Sia
O-acetylations (c.f., sections and relevant references above, and
additional Refs. 30,78,152–156). A library of over 70 synthetic
sialoglycans was thus produced, which is unique in that it con-
tains various pairs of Neu5Ac and Neu5Gc counterparts bear-
ing the same glycosidic linkages, underlying glycans and
spacers, that is, matched structures differing only by a single
oxygen atom. Moreover, many pairs were further diversified by
9-O-acetylation on the core Sia structures (Table I).46,157–160
This library is thus well suited for comparing protein recogni-
tion properties between Neu5Ac- and Neu5Gc-containing gly-
cans, as well as for exploring the effects of Sia O-acetylation on
binding. Furthermore, the number of sialoglycans in this
library is actively increasing. The Cummings and Smith group
also prepared a sialoglycan library in collaboration with one of
us. The library has 77 sialoglycans with 16 different Sia modifi-
cations based on three core Sia structures (Neu5Ac, Neu5Gc,
and Kdn), either a2-3 or a2-6 linked, and four different under-
lying glycan structures (Table I).158,161,162 Among the 16 modi-
fied Sias, 13 are naturally occurring and three have not yet
been found in nature. This sialoglycan library expanded the Sia
diversity formerly covered in glycan microarray systems by
adding the methylated and lactylated Sia structures. The Bovin
lab and Wong lab have two other libraries of sialoglycans, con-
taining about 40 and 30 different structures, respectively. Both
are synthetically produced, and most of them are Neu5Ac-
bearing structures (Table I).163–166 Besides monovalent sialo-
glycans, the Bovin lab also produced sialoglycans on PAA poly-
mer backbones and with additional functionalities such as
biotin or fluorescein labels. The Institute for Glycomics in Grif-
fiths University also has a library of 20 sialoglycans.167
Current Platforms for Sialoglycan Microarrays and
the Immobilization Chemistries
Based on the libraries discussed above, standard sialoglycan
microarray platforms have been developed. Typically, func-
tional group modified glass substrates are used to accommo-
date robotically printed microarrays that contain hundreds to
thousands of tiny sialoglycan solution spots. After incubation
to ensure proper attachment, the glycan microarrays are
blocked and are then ready for high-throughput screening
studies. Many immobilization chemistries have been developed
in the past decade.134,135 Although elegant proof-of-principle
studies regarding each chemistry have been extensively demon-
strated, most of them have not yet been tested broadly for
more advanced applications. In the case of sialoglycan microar-
rays, only three immobilization methods are widely used and
applied for various studies (Table I). These are chemistries
involving reactions of an amine with NHS-ester, or with epox-
ide, and noncovalent hydrophobic attachment. Occasionally,
the high affinity noncovalent biotin and streptavidin interac-
tion was utilized for immobilizing sialoglycans, but mostly in a
multiwell plate format.157,168,169
Besides the standard sialoglycan microarrays, a few mini-
sialoglycan array platforms appeared to couple with other
attractive techniques=technologies and provide interesting
potential. In 2008, the Cheng group in collaboration with one
of us reported a sialoglycan biosensor platform based on sur-
face plasmon resonance (SPR) spectroscopy, to study Sia-lectin
interactions in a label-free format and in real-time.170 The
biotin-neutravidin interaction was used to immobilize four
biotinylated Sias, Neu5Aca2-3Lac, Kdna2-3Lac, Neu5Aca2-
6Lac, and Kdna2-6Lac on the sensor chip and the system was
interrogated with a number of lectins. Interaction kinetics and
affinity data were obtained, and the effects of Sia structure and
linkage variations on lectin binding proved to be detectable by
the system. In 2009, a follow-up SPR imaging study was car-
ried out for more detailed characterizations of the sensor sur-
face chemistry and lectin interactions with additional
techniques including fluorescence microscopy and atomic
force microscopy (AFM).171 In 2011, the Flitsch group pre-
sented a platform to generate sialoglycans in situ on surfaces in
an array format and the synthesis was monitored by MALDI-
TOF (matrix-assisted laser desorption ionization time-of-
flight) mass spectrometry (MS). After completion of the in
situ chemoenzymatic reactions, the sialoglycan surfaces were
directly used for studying interactions by cells bearing
recombinant Siglecs.172 The authors demonstrated that a self-
assembled monolayer (SAM) surface was suitable for studying
whole mammalian cell interactions with limited nonspecific
interactions. Combination of glycan microarray and MALDI-
TOF techniques was also exploited to assess enzymatic activ-
ities and specificities of influenza neuraminidases from whole
viruses.173 However, this study used different surfaces and
immobilization chemistry. Their sialoglycan array took advant-
age of a DNA=DNA hybridization method and glass slides
bearing microreactors were produced to anchor the surface
DNA strand. In 2012, the Sun group reported two interesting
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developments involving sialoglycan microarrays.174,175 In one
case, two Neu5Ac-containing glycopolymers were chemoenzy-
matically synthesized. The Sias were a2-3- or a2-6-linked to
underlying lactose, and the polymer scaffold was functional-
ized with an O-cyanate group at the chain-end for surface
immobilization. The oligo-Sia macroligands were immobilized
to amine-functionalized glass slides via amine-O-cyanate
chemistry, leading to an oriented presentation of the Sia-
bearing polymer.174 The system was interrogated by a range of
lectins, in the presence or absence of free Sia competitors. An
SPR biosensor system was also developed based on the same
immobilization chemistry to study lectin and influenza hemag-
glutinin (HA) binding to the attached sialoglycan polymers.
The authors claim this system better mimics the 3D nature of
cell surface Sia presentation and should provide considerable
advantages for relevant studies. In the other study, Ma et al.175
fabricated a liposomal sialoglycan microarray by the Stau-
dinger ligation method. Gangliosides GM1 and GM3 inserted
liposomes were immobilized on glass slides and remained
intact, after which lectin and bacterial toxin bindings were
evaluated. This system was claimed to present sialoglycans on a
surface mimicking native cell membranes, and could thus be
deemed an important tool for various applications.
All of the above mentioned mini-sialoglycan array plat-
forms provide interesting additional functionality to the stand-
ard sialoglycan microarrays and show considerable promise.
However, most of these examples included only a few sialogly-
cans, and some systems were designed in a well-based array
format. Thus, expansion of the sialoglycan libraries and minia-
turization of the array spots in these systems are yet to be
explored, so that truly high-throughput evaluation of
sialoglycan-involved interactions can be realized.
Studying Sia-Recognizing Proteins by Sialoglycan
Microarrays
It is evident that Sia binding lectins can be found in many
microbes, plants and animals.98–102 Studies of these Sia-
recognizing proteins by sialoglycan microarrays are rapidly
growing. In part due to a joint effort between the CFG and the
Centers for Disease Control (CDC), and partly because of the
global public health concern=high importance of the topic,
the proteins from influenza viruses of various origins,
subtypes, clades, and strains have been extensively studied by
sialoglycan microarrays. These include influenza virus HAs
from various subtypes such as H5N1,138,139,141 H2N2,140,143
H1N1,164,165,176,177 and H3N2.164 As influenza virus HAs bind
to Sias, a central aim for these screenings has been to find out
whether the specificity could act as a pathogenic pandemic risk
factor. The molecular basis for difference of HA ligand specific-
ity between zoonotic influenza viruses and corresponding
human-adapted ones is being actively explored, however,
clearer relevance between the HA ligand specificity and the risk
of pathogenic pandemic is yet to be neatly demonstrated.
Wang et al.166 took a different approach to study the influ-
enza HAs using sialoglycan microarrays. They examined the
effects of HA glycosylation on its host receptor binding and
found that removal of certain glycan structures on viral surface
glycoproteins could result in higher-affinity Abs elicited and
better neutralization activities of these Abs. More recently,
both the influenza HA homologue from bat influenza virus
(H17N10) and the N10 neuraminidase-like protein from the
same origin were found to show no binding to ligands on the
CFG sialoglycan microarrays.178,179 In contrast, a neuramini-
dase mutant from human H3N2 influenza virus avidly bound
to Sia ligands on the sialoglycan microarrays. The observed
neuraminidase binding was of much higher affinity (lM
range) compared to HA bindings (usually low mM).180 Other
Sia-binding proteins from different types of viruses have been
studied by sialoglycan microarrays, including human JC polyo-
mavirus, serotype 1 reovirus, bovine coronavirus and canine
adenovirus,142,151,158,181 as well as parasites like Toxoplasma
gondii and Eimeria tenella.150,182
The sialoglycan microarrays derived from more extensive
glycan libraries (e.g., CFG and the Feizi group) have been used
to study specific proteins or microbes directly. However, the
two more recently established sialoglycan microarrays were
tested extensively against a wide range of proteins and
microbes, from common plant lectins to viruses.158,161
Because of their important roles in human immu-
nity,24,103,183,184 Siglecs are another type of favored candidates
for sialoglycan microarray studies.144,145,149,157,158 The Paulson
lab and the Chen lab utilized different chemical and chemoen-
zymatic methods to generate relatively large libraries of
unnatural and natural Sias in a high-throughput manner.
These libraries of Sias could be directly used for array fabrica-
tion and Siglec ligand identification.144,145,149,157 A few of the
unnatural Sia analogues generated by Rillahan et al.145 have
proved to be of high affinity to a range of Siglecs. Besides the
C-5 and C-9 position modifications on the Sia core structure,
the Kelm lab very recently showed that modifications at the Sia
C-4 position could act synergistically with C-9 modification
and also enhance Siglec binding.185 Higher affinity Sia ana-
logues could be potentially used as Siglec inhibitors or for tar-
geted therapeutic delivery to treat, for example, B cell
leukemia.145 However, Siglecs like CD22 are recently noted to
be expressed not only on B cells, but also on dendritic cells and
gastrointestinal eosinophils.186,187 Thus, precautions and extra
investigations are needed to successfully pursue this strategy.
Sialoglycan microarrays have also been used to identify can-
cer biomarkers. Taking advantage of its unique feature, the
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paired Neu5Gc=Neu5Ac sialoglycan microarray platform was
utilized in our labs to study the unusual anti-Neu5Gc Abs in
humans.46 Sera from cancer and noncancer patients were char-
acterized, and Abs against Neu5Gca2-6GalNAca1-O-Ser=Thr
(GcSTn) were found to be more prominently present in
patients with carcinomas than with other diseases. Further-
more, the corresponding patient sera and purified polyclonal
Abs which showed strong anti-GcSTn reactivity both proved
capable of killing human tumors expressing GcSTn, via either
complement-dependent cytotoxicity or Ab dependent cellular
cytotoxicity.46 This study was followed up by a detailed LC-MS
analysis of the polyclonal human anti-Neu5Gc Abs, and all
four IgG subclasses of Abs were confirmed to present after the
human immune response to the xeno-autoantigen Neu5Gc.159
The same sialoglycan microarray platform was also used to
detect anti-Neu5Gc Ab responses in patients with Kawasaki
Disease.160 Other glycan microarray platforms (including
microarrays with various non-Sia glycan epitopes), have also
been used to study complex samples like human sera and for
biomarker discoveries.106,163,188–191 Aside from studying Sia-
recognizing lectins and Abs, sialoglycan microarrays can also
be applied to measure enzymatic activities of various neurami-
nidases=sialidases.173,192 In addition, sialyltransferase reactions
have been monitored directly on glycan microarrays.172,193
Studying Viruses, Bacteria, and Whole Mammalian
Cells by Sialoglycan Microarrays
No matter what one finds using purified glycan-binding pro-
teins, there is always the possibility that the binding specificity
will be different when studying the intact organism that
expresses the same protein. Thus there is a need to study inter-
actions of intact organisms with arrays. To date, the most stud-
ied examples are influenza viruses. Receptor specificities of
human, avian, and porcine influenza viruses have been exam-
ined and comparisons among these strains have yielded
insights into the molecular basis for their receptor specificity,
transmissibility, as well as virulence.139,141,148,161,165,194–198 In
most of these studies, intact or biotinylated viruses were
applied to the sialoglycan microarrays and detected by
fluorochrome-labeled virus-binding Abs or streptavidin-
fluorochromes, respectively. However, fluorochrome-
conjugated viruses could be directly used for glycan microarray
studies.199 Other types of viruses were also studied by sialogly-
can microarrays. In 2007, a neoglycolipid microarray was used
to study receptor specificity of simian virus 40 (SV40), finding
that the N-glycolyl GM1 ganglioside was a preferred recep-
tor.200 Cell studies and molecular modeling further supported
the finding. Preferential binding to Neu5Gc over Neu5Ac
was also observed for some other viruses and bacterial tox-
ins.53,201–203 There are many more such proteins and microbes
that await exploration. The potential impact of this type of
preferential binding in host–pathogen interactions on human
health and disease warrants further research, and sialoglycan
microarrays containing pairs of Neu5Gc and Neu5Ac glycans
will serve as a novel platform for such investigations.
Surprisingly, there are very few reports to date on studying
intact bacteria using sialoglycan microarrays. In 2004, See-
berger and coworkers tested Escherichia coli binding on a dif-
ferent type of glycan microarray comprised of mannose (Man),
glucose (Glc), N-acetyl-glucosamine (GlcNAc), galactose (Gal),
or fucose (Fuc) structures. Unexpectedly, the printed glycan
microarrays with oligomannose structures showed no increase
in bacterial binding capacity compared to mono-mannose
arrays.204 The authors attributed this phenomenon to the pos-
sibility that the tested bacterial stain only required a single
mannose residue for recognition and the multivalency of man-
nose and stereochemistry of the intermannose linkages played
little role. However, a more recent study from the same group
showed that trimannose and nonamannose structures attached
to a cantilever array sensor tip did show differential binding
affinities to the same E. coli strain tested earlier, indicating an
increased multisite and multivalent binding for the nonaman-
nose structure compared to less complex mannose struc-
tures.205 Taken together, these studies showed a need to
improve the glycan microarray platform for studying intact
bacteria. In this regard we have recently embarked on using sia-
loglycan microarrays to investigate a group of Gram-positive
bacteria (Deng and Varki, et al., unpublished observations).
Bacterial adhesins=mutants and corresponding intact isogenic
strains are being tested on printed sialoglycan microarrays, and
after careful optimization, the data show interesting correla-
tions between ligand spectra=affinity and virulence. The effect
of shear force on bacterial binding also needs investigation.
Testing whole mammalian cells on sialoglycan microarrays
is also an emerging endeavor. Although whole cell bindings
were demonstrated in a millimeter-spot-sized microarray sys-
tem as early as in 2004,206 robotically printed micrometer-
sized glycan arrays have not been used to study whole
mammalian cells until very recently.145,167 Rillahan et al.145
demonstrated binding of Siglec-bearing Chinese hamster
ovary (CHO) cells and CD22-expressing human B-cells on
their Sia analogue microarrays. In another report, Arndt
et al.167 tested a range of human cancer cell lines directly on
their glycan microarrays (various types of glycans, not com-
pletely sialoglycans) and on a lectin microarray, and they
found an inverse relationship between how many glycans the
tested cells could recognize and how many types of intrinsic
glycans were expressed on those cells. This study also pointed
to the importance of characterizing=evaluating cell surface
glycosylation status when using those common laboratory cell
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lines for cell-based assays. Well-plate based glycan arrays have
also been developed for studies of glycan-cell interactions
recently.172,207 Initial efforts to pair the screening of binding
specificity of secreted proteins with corresponding protein-
bearing cells are currently undertaken as well.208
Decoding Clustered Saccharide Patches by
Sialoglycan Microarrays
Current glycan microarray platforms are usually composed of
individual spots each displaying a single glycan structure.
However, cell surfaces present glycans in a highly heterogene-
ous fashion. Thus there is also a need to try to explore glycan–
protein interactions in a manner more similar to the natural
state. Although difficult to prove conclusively, the hypothesis
of clustered saccharide patches is worth testing.67,82,86,209 The
information gained could further enhance our understanding
of glycan–protein interactions and improve drug design strat-
egies. This concept can be to some extent tested using glycan
microarrays.
In 2010, Wu and coworkers210 published a glycan microar-
ray design of such a nature. They spotted the glass slides with
mixed glycans, for example, SSEA4=Gb5, Globo H=Gb5,
Gb4=Gb5, Gb3=Gb5, Gb2=Gb5, Bb2=Gb5, in 1:1 molar ratio
and interrogated the slides with anti-Gb5 Ab. Interestingly, the
SSEA4=Gb5 mixed glycan spot consistently showed higher
binding than the Gb5-alone glycan spot. On the other hand,
neighboring glycans could also exert a negative effect on the
Gb5 and anti-Gb5 interaction, possibly via steric hindrance, as
evidenced by lower binding of the other mixed glycan spots
compared to the Gb5-alone spot. Further tests were done by
mixing glycans in varied concentrations and by using synthetic
oligomannose dendrimers containing different ratios of Man4
and Man9 structures. Both experiments demonstrated Ab
binding could be affected by the density and structures of
neighboring glycans. In parallel, the Willison lab combined a
few techniques and recently produced polyvinylidene difluo-
ride membranes (PVDM) affixed glass slides for the generation
of sialoglycan (ganglioside) microarrays. They called this
setup a “combinatorial glycoarray,” and used it primarily to
study neuropathy-associated anti-glycolipid autoantibod-
ies.211,212 These Abs specifically recognize complexes of glyco-
lipid pairs, but fail to interact with either of the glycolipids
alone. Other exciting developments include that relatively sta-
ble lipid bilayer coated glycan microarray slides have been
readily made. This is promising due to its better mimicry of
the cell surface features.213,214 It can be envisaged that this type
of surface may serve as an ideal platform for decoding the
effects of clustered saccharide patches on protein and cell
bindings.
COMPARISONS OF SIALOGLYCAN
MICROARRAY PLATFORMS
In the DNA microarray field, the microarray quality control
(MAQC) consortium has been established and major efforts
toward standardization of processing and reporting microarray
data have been made.215,216 As the number of new glycan
microarray platforms continues to grow and applications using
these platforms expand, the need for cross-comparison among
platforms and established guidelines for glycan microarray
experiments has become increasingly relevant and urgent.
In 2012, two labs took the initiative and cross-compared
their newly developed sialoglycan microarray platforms, both
developed using the same chemistries.158 These two glycan
microarrays presented comparable sialoglycans produced by
the same synthetic strategy from the same group. However, the
immobilization chemistries used for attaching the sialoglycans
on the two platforms were different, and the linkage monosac-
charide ring was opened in one of the two arrays. These micro-
arrays were reciprocally tested against various Sia-binding
proteins and analyzed in the two labs.158 This comparison
yielded a lot of useful information but also identified major
challenges in the standardization of glycan microarray experi-
ments. For instance, immobilization methods appeared to
strongly influence some binding results. Also, the close-ring
immobilization method was evidently critical for some glycan-
recognition events, and an open-ring immobilization could
sometimes lead to the absence of detectable binding. This is in
keeping with another intragroup comparison of glycan micro-
arrays differing only in the immobilization method, where it
was found that the ring-closed immobilization method was
critical for many glycan-recognition events.217 Lower signal-to-
noise ratio bindings based on open-ring immobilization
method was also observed in another independent array com-
parison study.162 Besides these, binding data with various gly-
cans from the same source but arrayed at different locations
were also compared and reported.218 More recently, a larger
scale glycan microarray comparison involving five different
research groups has been carried out (personal communication
from Dr. Lara K. Mahal, NYU).
CONCLUSIONS AND PERSPECTIVES
The diversity and biology of Sias represent part of the vast
information and knowledge gained in the field of glycoscien-
ces. It is evident that sialoglycan microarrays are playing an
increasingly important role in elucidating this diversity and
biology. During the past decade, the advancement of glycan
microarray development and applications is indeed highly
laudable and exemplary; however, there is still plenty of room
for further developments and improvements.
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1. Larger libraries of sialoglycans, consisting of either nat-
ural structures or synthetic analogues, are still greatly
desired. Just by comparing currently available sialogly-
can libraries and the diversity of Sia structures occur-
ring in nature12 one can realize how big the gap is,
let alone the unlimited possibilities of synthetic Sia ana-
logues. For example, it will be interesting to see sialo-
glycan microarrays made of 4-O-acetylated Sias or
polySias. These structures are largely un-explored by
sialoglycan microarrays. In addition, current efforts are
mainly focused on elucidating binding of terminal gly-
can sequences. However, binding effects resulting from
intact natural sialoglycan classes and underlying pepti-
des=lipids have to be further evaluated.
2. Sialoglycan microarrays have shown to be a suitable
platform to demonstrate the concept of clustered sac-
charide patches. Further studies such as mixing more
components in a single glycan spot, controlling spacing
between glycans in the spot, and testing their effects on
protein binding, are worthwhile.
3. Ligand specificity of many more Sia-recognizing pro-
teins, viruses, bacteria and whole mammalian cells are
worthy of investigation in detail.98–102 This would
require more extensive collaborations between glyco-
scientists (chemists and biologists) and researchers
from other fields, such as microbiologists. The joint
effort will certainly benefit all parties involved.
4. To date, more than 20 different types of immobilization
methods for glycan microarray fabrication have been
developed.134,135 For example, the immobilization of
glycans by photochemistry is a highly versatile and effi-
cient method.219 This can be realized by producing
photoprobe-derivatized glycans,220 direct attachment of
underivatized glycans,221 or a “photo-click” hybrid
method.222 Photogenerated glycan microarrays have
also been successfully applied to identify immunogenic
glycan antigens specific to certain bacterium.223 How-
ever, most of the immobilization methods developed to
date were only demonstrated in proof-of-concept type
of studies. The exceptional versatility and efficiency of
the photochemical immobilization methods warrant
further development and broader applications. Cross-
comparison of these immobilization methods and
insight into their merits and disadvantages are needed
for further microarray standardization and
applications.
5. Technical issues such as Sia contamination of the most
widely used glycan microarray blocking reagent bovine
serum albumin (BSA) (our observations, unpublished
result), and sample dilution effects,224 and so forth, are
also important considerations in conducting glycan
microarray experiments and analyzing glycan microar-
ray data.
6. Initial efforts have been undertaken, but the cross-
comparison and standardization of sialoglycan microar-
ray experiments and microarray data processing has a
long way to go. Guiding rules for the interpretation of
glycan microarray data are also to be established. More-
over, building common glycan microarray databases
and further enabling relevant glycobioinformatics
would be very helpful and beneficial to the entire glyco-
science community.225
7. Combination of glycan microarrays with other methods
and techniques will, on the one hand, help validate the
glycan microarray data, and on the other hand, often
add another dimension to the findings. For example,
real-time monitoring of the binding events and addi-
tional binding kinetics data can be obtained with bio-
sensors like SPR220,221 and quartz crystal microbalance
(QCM).222,226 Isothermal titration calorimetry (ITC)
can provide thermodynamic information,227 and
detailed single molecular interaction data can be
acquired by using AFM.228 Combination of microarrays
with nanotechnology can greatly enhance the sensitivity
of detection.229,230 Furthermore, comparisons with
other assays like enzyme-linked immunosorbent assay
(ELISA) and dot blots,231,232 and combination with
MS, computational modeling, X-ray crystallography,
etc., have been and will continue to play major roles in
the elucidation of glycan–protein interactions.
8. After glycan microarray screening of glycan–protein
interactions and complementary methods to validate
the bindings, follow-up biomedical and=or biological
studies are critical. These will ultimately move the ini-
tial findings into more clinically and=or biologically rel-
evant and more profound discoveries=applications to
combat diseases and benefit human health.
9. This review focused on studies of Sia diversity and biol-
ogy by using sialoglycan microarrays, but the concepts,
trends, and ideas discussed in this incomplete survey
are readily applicable to other types of glycans and gly-
can microarrays.
The authors thank Miriam Cohen, Jerry Fong, and Stevan Springer for
helpful comments.
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